ReviewWorld journal of microbiology & biotechnology2026
A comprehensive review of microbial exopolysaccharide for bioremediation of environmental pollutants and industrial waste toxicants using sustainable strategies: bottlenecks and future perspectives.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial exopolysaccharides (EPS) offer efficient and sustainable approaches to remediate environmental pollutants. Its distinctive structural features, abundant in functional groups including carboxyl, hydroxyl, phosphate, sulfate, and amino groups, facilitate robust interactions with heavy metals, petrochemical residues, industrial dyes, and many hazardous pollutants. EPS promotes the removal of pollutants through various physico-chemical interactive mechanisms, such as chelation/complexation, biosorption, ion exchange, bioflocculation, and emulsification. EPS may demonstrate pollutant-binding and detoxification potential of contaminants such as Pb²⁺, Cd²⁺, Cr⁶⁺, polycyclic aromatic hydrocarbons (PAHs), crude oil hydrocarbons, and synthetic colors under laboratory conditions, though efficiency varies with environmental parameters and pollutant complexity. However, no commercialized bio-product is available that employs green, sustainable strategies to eliminate health-hazardous pollutants. The regulatory consequences of EPS-based product development are under-researched. A comprehensive review of sustainable green strategies for EPS-based bioreactors to treat environmental pollutants, heavy metals, and industrial waste/dye effluents in wastewater is discussed. Study highlights limitations and deficiencies in bioremediation using reinforcement strategies. It explores future research directions for the practical implementation of EPS-based nanotechnology, photocatalytic skills, carbon nanodot matrices, and biochar sludges to enhance sorption capacity and provide workable solutions for a satisfactory bioremediation process, though challenges remain in recovery, stability, and large-scale application. It evaluates cost-effective, high-performance EPS bio-material designs, while noting that scalability and regulatory approval remain critical challenges to deployment. It assesses the functional properties, pollutant-interaction mechanisms, and bioremediation efficiency of EPS, demonstrating their potential as environmentally safe, biodegradable, renewable, and biocompatible biomaterials for scientists seeking to develop efficient methods to treat extreme industrial wastewater and reclaim valuable resources. The review elucidates how EPS-based biodevices showcase promise for pollutant removal, addresses bottlenecks to progress, and outlines future directions, where industrial deployment is limited by production costs, yield variability, and regulatory gaps.
Indexed as
Identifiers
42565882What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.